Cadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 3,898 Shares

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CEO Quang Pham sold 3,898 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $4.41, for a total value of $17,190.18. Following the transaction, the chief executive officer owned 175,288 shares of the company’s stock, valued at $773,020.08. This trade represents a 2.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Price Performance

Cadrenal Therapeutics stock opened at $4.44 on Friday. The company has a market capitalization of $12.73 million, a PE ratio of -0.79 and a beta of 1.59. Cadrenal Therapeutics, Inc. has a one year low of $4.14 and a one year high of $15.99. The business has a 50 day simple moving average of $5.13 and a 200 day simple moving average of $6.92.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its earnings results on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, topping the consensus estimate of ($1.51) by $0.47. Equities analysts anticipate that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cadrenal Therapeutics

Institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. acquired a new stake in shares of Cadrenal Therapeutics during the third quarter worth $103,000. Geode Capital Management LLC grew its stake in shares of Cadrenal Therapeutics by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after purchasing an additional 1,818 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Cadrenal Therapeutics during the third quarter worth $274,000. Finally, DRW Securities LLC acquired a new stake in shares of Cadrenal Therapeutics during the fourth quarter worth $171,000. 7.92% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CVKD shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Monday, April 20th. HC Wainwright dropped their price target on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Finally, Wall Street Zen raised Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cadrenal Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.